LL-37 as a Powerful Molecular Tool for Boosting the Performance of Ex Vivo-Produced Human Dendritic Cells for Cancer Immunotherapy

Ex vivo-produced dendritic cells (DCs) constitute the core of active cellular immunotherapy (ACI) for cancer treatment. After many disappointments in clinical trials, the current protocols for their preparation are attempting to boost their therapeutic efficacy by enhancing their functionality towar...

Descripción completa

Detalles Bibliográficos
Autores principales: Stakheev, Dmitry, Taborska, Pavla, Kalkusova, Katerina, Bartunkova, Jirina, Smrz, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780902/
https://www.ncbi.nlm.nih.gov/pubmed/36559241
http://dx.doi.org/10.3390/pharmaceutics14122747

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780902/
https://www.ncbi.nlm.nih.gov/pubmed/36559241
http://dx.doi.org/10.3390/pharmaceutics14122747

Ejemplares similares